A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission. This case emphasises that management with the targeted immunomodulatory agent dupilumab, which has minimal adverse impact on ICI efficacy, can be effective for cirAEs, including steroid‐refractory PL‐like eruptions, and may allow for continuation of ICI treatment.